CONFLICT OF INTEREST STATEMENT
NC is or recently was a speaker and/or advisor for and/or has received
research funding from argenx and Onward Therapeutics and is inventor on
patents related to compositions and methods for treating or preventing
lupus (W020120710042 & WO2016128565A1); IKK received research funding
from Sanofi Regeneron, Pfizer and AbbVie; EK has no conflicts of
interest regarding any aspects of this study; JS has conducted studies
for, received research funds/was advisor for Allakos, Ascilion,
AstraZeneca, CSL Behring, Celldex, Genentech, Escient, Novartis, Sanofi,
Servier, ThirdHarmonicBio, ThirdRock and ThermoFisher; SA is or recently
was a speaker and/or advisor for and/or has received research funding
from AstraZeneca, Allakos, CSL Behring, Sanofi, Takeda, ThermoFisher,
Moxie, and Novartis; CS has no conflicts of interest regarding any
aspects of this study; Y-KX has no conflicts of interest regarding any
aspects of this study; JG has no conflicts of interest regarding any
aspects of this study; LLR is or recently was a speaker and/or advisor
for and/or has received research funding from Argenx, Novartis, Ceva and
Neovacs, and is inventor on patents issued or pending relating to IgE
detection and anti-IgE therapies: EP2021/060829, EP20315224-4,
WO2019197607 (A1); MM is or recently was a speaker and/or advisor for
and/or has received research funding from Allakos, Amgen, Aralez,
ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech,
GIInnovation, GSK, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly,
Menarini, Merckle Recordati, Moxie, MSD, Novartis, Pfizer, Roche,
Sanofi/Regeneron, Third Harmonic Bio, UCB, and Uriach.